AI vs. Red Tape: SamaCare's Data Engine Tackles Healthcare Delays

SAN FRANCISCO, CA – February 17, 2026 – Health technology firm SamaCare announced it has processed over $6.2 billion in prior authorizations for specialty drugs in 2025, a milestone that signals the growing influence of artificial intelligence in untangling one of modern healthcare's most notorious knots. The company’s platform, which now supports 40% of the U.S. ambulatory infusion center market, leverages a massive dataset to accelerate approvals for life-saving medications, potentially reshaping access for patients with complex conditions.

Prior authorization (PA), the process requiring providers to get pre-approval from payers for certain treatments, has long been a source of frustration and delay. A 2022 American Medical Association (AMA) survey found that 93% of physicians report PAs delay access to necessary care, with a third stating these delays have led to a serious adverse event for a patient. SamaCare's announcement places it at the forefront of a technological arms race to solve this problem, using data as its primary weapon.

The Power of a $6.2 Billion Data Set

At the heart of SamaCare's strategy is the sheer volume of its data. The $6.2 billion in specialty drug PAs—spanning complex fields like oncology, neurology, and rheumatology—is derived from a network of thousands of provider locations. This has allowed the company to build what it claims is the largest real-time dataset on medical benefit drug prior authorizations in the country, trained on over two million individual PA submissions.

This scale is not just a vanity metric; it is the fuel for the company's AI engine. By analyzing millions of interactions across countless combinations of providers, payers, and specific health plans, the platform identifies patterns that would be invisible to a single human or practice. It learns which submission pathways are fastest, what documentation is most frequently required for a particular drug under a specific plan, and which common errors lead to automatic denials. This creates a powerful competitive advantage, as each new authorization submitted to the platform further refines the AI's intelligence, creating a virtuous cycle that competitors may find difficult to replicate.

The impact is particularly pronounced in the ambulatory infusion center market, where SamaCare saw a 70% year-over-year increase in PA volume. This niche focuses on "buy-and-bill" drugs—expensive specialty medications that providers purchase upfront and are reimbursed for later—a process fraught with financial risk and administrative complexity. By streamlining approvals, the platform mitigates this risk for providers and helps ensure that treatments for conditions like cancer and multiple sclerosis are not held up by paperwork.

From Red Tape to Faster Treatment

For patients and their doctors, the administrative labyrinth of prior authorization can feel like an insurmountable barrier. SamaCare aims to replace that labyrinth with a guided path, claiming its platform can improve patient access to specialty medications by 40% to 90%.

"For providers, this isn't just about saving time," said Syam Palakurthy, Founder and CEO of SamaCare, in the company's announcement. "Every prior authorization represents a patient waiting for treatment. By embedding the collective experience of thousands of practices into the workflow, SamaCare helps clinics avoid known pitfalls, reduce unnecessary delays, and understand in real-time how each authorization compares to what should be happening."

The company emphasizes that its platform is not a "black box" where decisions are made by an opaque algorithm. Instead, it provides transparent, interactive guidance, showing staff why a specific form or piece of documentation is recommended. This hybrid model, combining AI-driven recommendations with human oversight, is designed to build trust and empower administrative staff, not replace them. For pharmaceutical partners, SamaCare has reported results such as an 84% reduction in time-to-approval and a 24% drop in patient abandonment rates for prescribed therapies, translating directly into better health outcomes.

This approach stands in stark contrast to the traditional, manual process of phone calls, faxes, and navigating disparate payer portals. While other companies like Cohere Health and Rhyme are also deploying AI to tackle this issue, SamaCare's deep focus on the complex specialty drug market and its massive, proprietary dataset serve as key differentiators.

Navigating a Shifting Regulatory Landscape

SamaCare's growth comes as federal and state regulators are intensifying their scrutiny of prior authorization processes and the use of AI in healthcare decisions. This evolving regulatory environment presents both a significant opportunity and a potential challenge for companies in the space.

The Centers for Medicare & Medicaid Services (CMS) has finalized new rules that will force a sea change in the industry. By 2026, payers will be required to provide PA decisions within 72 hours for urgent requests and seven calendar days for standard requests—a dramatic acceleration from current timelines. These mandates are creating immense pressure on health plans to adopt technology that can meet the new efficiency standards, effectively creating a tailwind for solutions like SamaCare's.

However, this push for speed is tempered by growing concerns about algorithmic bias and accountability. In response, regulators are erecting guardrails. California enacted a law in January 2025 that prohibits payers from making coverage decisions based solely on AI, requiring review by a qualified healthcare professional for any denial or delay of care. Similar legislation has been passed or introduced in states like Texas, Illinois, and Maryland, reflecting a broad consensus that AI should augment, not replace, human clinical judgment.

This regulatory climate has been shaped by high-profile lawsuits against major insurers like UnitedHealth Group and Humana over their alleged use of AI tools to improperly deny care. By positioning its platform as a transparent tool that assists human decision-makers, SamaCare appears to be navigating this complex terrain carefully, aiming to be seen as part of the solution to regulatory demands rather than a target of them.

A New Battleground for Pharma and Payers

The rise of sophisticated PA platforms is transforming the strategic landscape for pharmaceutical manufacturers and payers alike. For pharma companies that produce high-cost specialty drugs, ensuring patients can access their therapies is a critical commercial challenge. Delays and denials in the prior authorization process directly lead to lost revenue and, more importantly, patients who fail to receive a prescribed treatment.

SamaCare offers these manufacturers a powerful toolkit. Its platform provides unprecedented visibility into payer behavior, highlighting which health plans or policies are creating the most friction. This data allows pharma companies to better target their support and education efforts. Furthermore, by streamlining the process at the provider level, the platform directly helps convert a prescription into a filled treatment, reducing patient abandonment and improving adherence.

For payers, the proliferation of AI-driven PA tools represents a new reality. While they have historically held the keys to the kingdom through their complex and often opaque PA requirements, platforms like SamaCare are standardizing and illuminating the process. This levels the playing field for providers and, coupled with new CMS mandates for transparency and speed, will force payers to become more efficient and justify their decisions with greater clarity. The era of winning through administrative complexity may be drawing to a close, replaced by a new environment where data-driven efficiency and clear, evidence-based rules define the interaction between payers, providers, and the technologies that connect them.